drugset / Trial / NCT02314377

Bevacizumab Therapy for Brain Arteriovenous Malformation

NCT02314377 ↗

Phase 1 Completed 2 enrolled University of California, San Francisco
NaSingle-groupOpen-labelTreatment

Summary

Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.

Timeline

Start
2016-06
Primary completion
2018-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg —